Piper Sandler Raises Viatris Target to $12, Launches Inpefa in UAE
Piper Sandler raised Viatris’s price target to $12 from $9 on Jan. 28, keeping a Neutral rating based on brand-business strength and expected stable contributions in developed markets. On Jan. 20 Viatris launched Inpefa® (sotagliflozin) in the UAE as its first dual SGLT1/2 inhibitor rollout outside the U.S. and Europe.
1. Piper Sandler Rating Update
On Jan. 28 Piper Sandler increased its price target for Viatris to $12 from $9 while maintaining a Neutral rating. The firm cited strength in the company’s brand business across multiple geographies and anticipated continued steady contributions in developed markets from upcoming product launches ahead of quarterly results.
2. Inpefa Launch in UAE
On Jan. 20 Viatris launched Inpefa® (sotagliflozin) in the United Arab Emirates, marking its first commercialization of the dual SGLT1/2 inhibitor outside the U.S. and Europe. This milestone reflects the company’s strategy to extend treatment access in key markets beyond its traditional regions.
3. Inpefa Approval and Outlook
Inpefa is approved in the UAE and the United States to reduce hospitalization for heart failure, cardiovascular death and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. Viatris plans additional launches in multiple countries over the coming years to bolster its global cardiovascular portfolio.